Literature DB >> 8327117

Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases.

L Pierot1, C Sauve, J M Leger, N Martin, A C Koeger, B Wechsler, J Chiras.   

Abstract

Fifteen patients with Sjögren's syndrome without clinical evidence of central nervous system disease were studied by MRI. Signal abnormalities were observed in 9 (60%). They were always visible on T2-weighted images as small punctate areas of high signal in the basal ganglia and the white matter of the cerebral hemispheres. Abnormalities were less frequently seen on T1-weighted images. Enlargement of cerebral sulci was observed in 6 cases. The specificity and significance of these abnormalities are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8327117     DOI: 10.1007/bf00588375

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  18 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Magnetic resonance imaging of cerebral lesions in patients with the Sjögren syndrome.

Authors:  E L Alexander; S S Beall; B Gordon; O A Selnes; G D Yannakakis; N Patronas; T T Provost; H F McFarland
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

Review 3.  [Central and peripheral neurologic lesions in primary Gougerot-Sjögren syndrome. Clinicopathological study of a case].

Authors:  S Bakchine; C Duyckaerts; L Hassine; M P Chaunu; E Turell; B Wechsler; F Chain
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

Review 4.  Imaging of the aging brain. Part I. Normal findings.

Authors:  B P Drayer
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement.

Authors:  H B Kaltreider; N Talal
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

6.  MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potential findings.

Authors:  D Uhlenbrock; D Seidel; W Gehlen; H K Beyer; J Haan; E Dickmann; T Zeit; E Herbe
Journal:  AJNR Am J Neuroradiol       Date:  1988 Jan-Feb       Impact factor: 3.825

7.  Neurologic complications of primary Sjögren's syndrome.

Authors:  E L Alexander; T T Provost; M B Stevens; G E Alexander
Journal:  Medicine (Baltimore)       Date:  1982-07       Impact factor: 1.889

8.  [Neuro-psychiatric symptom associated with primary Sjögren's syndrome].

Authors:  M Mukai; A Sagawa; Y Baba; Y Amasaki; K Katsumata; M Yoshikawa; T Nakabayashi; I Watanabe; I Yasuda; A Fujisaku
Journal:  Ryumachi       Date:  1990-04

9.  [Periarteritis nodosa: clinical and therapeutic study of 126 patients followed-up during 23 years].

Authors:  L Guillevin; J Fechner; P Godeau; O Blétry; B Wechsler; G Herreman; S Herson
Journal:  Ann Med Interne (Paris)       Date:  1985

10.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05
View more
  4 in total

1.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

2.  Primary Sjögren's syndrome in chronic polyneuropathy presenting in middle or old age.

Authors:  J M Leger; P Bouche; P Cervera; J J Hauw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

Review 3.  Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.

Authors:  Gerwyn Morris; Michael Berk; Ken Walder; Michael Maes
Journal:  BMC Med       Date:  2015-02-06       Impact factor: 8.775

Review 4.  Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature.

Authors:  Apoorva Jayarangaiah; Rahul Sehgal; Narendranath Epperla
Journal:  BMC Neurol       Date:  2014-10-09       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.